Major Milestones Met
The management of Abattis Bioceuticals Corp (OTCPINK:ATTBF)
(CNSX:FLU) is pleased to provide this year in review update to
highlight the corporate accomplishments made in the last 12
months.
The past 12 months have been quite active for Abattis,
management has constructed a solid foundation for the framework of
our enterprise. We have met several significant milestones since
March of 2012 when we acquired 100 percent of the shares in Animo
Wellness Corporation. This marked the beginning of a timeline
filled with milestones that put Abattis in a position to be a fully
integrated bioceutical company to grow, value add process, produce,
license and market proprietary materials and products containing
standardized phytochemicals for sale into pharmaceuticals,
nutraceuticals, cosmetics, and animal nutrition markets.
In May 2012 we announced a 5 year distribution agreement with a
National Canadian Distributor and elected to hold off on marketing
the “me too” health products in favor of continuing to increase the
proprietary intellectual property pipeline of the company.
In August 2012 the company closed the deal which acquired the
shares of Northern Vine Canada Inc. and the acquisition of the
assets of Sci-Naturals Wellness Corp.. Northern Vine is a cGMP
facility licensed by Health Canada for the production of Natural
Health products and has the capacity to import and export bulk
materials, produce and package finished natural health supplements
for sale in most international markets.
In September 2012 the company acquired a one of a kind
extraction technology coined FFE for Flash Freeze Extraction and
has the rights to make copies. This revolutionary high quality
technology and equipment is ideal for the extraction of oils,
oleoresins and secondary products from natural biomasses. Its
technology, tagged “FFE” for Flash-Freeze Extraction, offers
dramatic improvements over the existing extraction methods, such as
CO2, steam distillation or solvent extractions. This breakthrough
process, operating in a closed loop system, has the following key
advantages:
-It produces extracts of so-far unseen quality, with high purity
and low solvent ontamination (closer to nature).
-FFE delivers higher extraction yields than most established
extraction methods.
-The system costs dramatically less to operate, is compact and is
fully scalable.
-The process is cleaner and environmentally friendly.
In addition to the technology acquisition the company acquired
over 400 related Internet domains for use in the company’s online
strategy. These are key in ensuring Abattis and its related
companies and business customers own their piece of real estate on
the Internet.
In November 2012 Abattis executed a formal License Agreement
(the "License Agreement") with Vertical Designs Ltd. ("Vertical
Designs") pursuant to which Vertical Designs granted a Bio-Pharma
license to the Company, which permits Abattis to now grow and
produce plants targeted for health and wellness, plant materials
and extracts in licensed facilities that it builds in British
Columbia utilizing Vertical Design's patented technology. In
addition, Abattismay purchase equipment from Vertical Designs for
use at such facilities. Abattis retains the sale and marketing
rights attached to all products grown or produced by it at these
licensed facilities.
In December 2012 this agreement was amended and Abattis now owns
the exclusive, worldwide rights to a patent license, with the right
to grant sublicenses, to use the Bio-Pharma technology for growing
products at licensed facilities, which products may only be used as
ingredients in the pharmaceutical, nutraceutical, cosmetic and
wellness markets.
On December 15th 2012 Health Canada published its new guidelines
and policies for the introduction of its Licensed Producer Program.
These changes came on the heals of two states (Washington and
Colorado) in the US voting to legalize the possession of
recreational Marijuana. Many other states have legalized medicinal
marijuana and it is sold in dispensaries to licensed patient
cardholders.
In January 2013 the company signed a consulting agreement with
Mr. Georges Laraque. Georges is well known for his long 12-year
career in the NHL and as Deputy Leader to the Green Party of
Canada. Another addition to the Abattis team in January was Dr.
Andrew Riseman Ph.D. Associate Professor, Applied Biology and Plant
Breeding at UBC. Dr. Riseman will be assisting the Company in
Applied Biology and Plant Sciences.
In February 2013 we announced the engagement of the British
Columbia Institute of Technology “BCIT” to study the growth rates
and novel compounds present in baby spinach and serve as a
benchmark for growing, processing and the proprietary extraction of
botanicals under strict Standard Operating Protocols to achieve
pharmaceutical grade products. This is our first step toward
producing bio-pharma grade botanicals that are standardized to
targetedphytochemicals. The company is focused on the controlled
and sustainable production of plants to meet the demand for a
traceable and consistent supply of botanical materials for
development of biopharmaceuticals. Also in February the company
announced the engagement of Triangle Consultants to
representAbattis at the various government levels across Canada as
it applies its strategic business approach for its
shareholders.
March has already proven to be a busy month already. We have
acquired BioCell Labs Inc and North American BioExtracts Inc. we
also signed a multi-million dollar supply agreement with Cromogen
Biotechnologies to purchase Cannabidiol or "CBD's" for the use of
creating infused products to be sold in the US Natural Health
Product Market(s). Under the terms of the agreement the CBD's being
supplied to Abattis are not listed as Scheduled 1
Drugs.Cannabinoids are a group of 21-carbon--containing
terpenophenolic compounds produced uniquely by Cannabis sativa and
Cannabis indica species. These plant-derived compounds may be
referred to as phytocannabinoids. Although
delta-9-tetrahydrocannabinol (THC) is the primary psychoactive
ingredient, other known compounds with biologic activity are
cannabinol, cannabidiol (CBD), cannabichromene, cannabigerol,
tetrahydrocannabivarin, and delta-8-THC. Cannabidiol, in
particular, is thought to have significant analgesic and
anti-inflammatory activity without the psychoactive effect (high)
of delta-9-THC.Source National Cancer Institute at NIH. With the
acquisition of BioCell Labs Inc., objective is to develop and
eventually commercialize Cannabis products, through a production
permit issued by Health Canada, addressing the medical needs of
patients who hold a license through the Marihuana Medical Access
Program.
Biocell Labs Inc then announced the appointment of Dr. Paula
Brown to the Board of Directors and as the Chief Science Officer of
the company. As Director of the BC Institute of Technology's
Natural Health and Food Products Research Group, has been actively
supporting the NHP industry for over a decade through applied
research activities including product development, establishment of
quality standards and regulatory compliance. Brown has reviewed and
contributed to several American Herbal Pharmacopeia Monographs
including Aloe Vera, Black Cohosh and Ginseng.
Also in March Abattis signed a letter of intent with Crudessence
Kombucha Inc. ("RISE") http://www.risekombucha.com/en/ to
acquire the worldwide exclusive license "the License" to produce,
distribute, market and sell a Kombucha tea infused or blended with
additional nutraceutical and bioceuticalformulas developed and
owned by Abattis and its subsidiaries. the purpose of the LOI is to
enable Abattis to initially bring a new brand of Cannabidiol CBD
infused probiotic functional beverages to the markets starting in
Washington and Colorado, the brand will be launched as "Cannabucha
Sun RiseTM" this product will be the first of its kind with infused
Cannabidiol "CBD" with the probiotic effects to create one of the
best possible health drinks in the world.
The Vertical Advanced Growing Systems “VAGS” can grow thousands
of types of plants and to demonstrate this the company also
announced in March its participation in a research project led by
Pamela Weathers, Professor of Biology and Biotechnology at
Worcester Polytechnic Institute (WPI) in Worcester, Mass. The
project is investigating a whole plant (of which Abattis will grow
for the project) therapeutic for treating malaria and other
diseases, one that may also reduce drug resistance.
Most recently the company announced its sponsorship for the
first ever cannabis (cannabis sp.) monograph and therapeutic
compendium currently under development by the American Herbal
Pharmacopoeia (AHP). http://www.herbal-ahp.org. The monograph,
scheduled for release in Spring 2013, will provide industry with a
variety of scientifically valid analytical methods suitable for use
in the identification, purity, and quality assessment of cannabis
and its crude products. . The world needs standards for Cannabis
and the many phytochemicals that come from it so lawmakers can
properly categorize them and so formulators can legally apply the
compounds in appropriate products that help those who are suffering
from various chronic diseases.
As we continued to build our company foundation, losses have
been reduced from .14 cents two years ago to .09 cents a share
while increasing our net and intangible tangible assets. We
continue to position the company in markets where high growth
opportunity exists and as the company matures we look forward to
continued success by utilizing the synergies of the people and from
the intellectual property we have acquired during these past 12
months. With many of the resources in place the company can now
begin to implement its Grow, Dry, Extract, Refine and Science
“GDERS” strategy.
For more information, visit the company's website at
www.abattis.com.
ON BEHALF OF THE BOARD
“Michael Withrow”
Michael Withrow, President & CEO
Neither the CNSX Exchange nor its regulations services accepts
responsibility for the adequacy or accuracy of this release.
Forward-looking information
All statements included in this press release that address
activities, events or developments that the Company expects,
believes or anticipates will or may occur in the future are
forward-looking statements. These forward-looking statements
involve numerous assumptions made by the Company based on its
experience, perception of historical trends, current conditions,
expected future developments and other factors it believes are
appropriate in the circumstances. In addition, these
statements involve substantial known and unknown risks and
uncertainties that contribute to the possibility that the
predictions, forecasts, projections and other forward-looking
statements will prove inaccurate, certain of which are beyond the
Company’s control. There can be no assurance that any
forward-looking statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should
not place undue reliance on forward-looking statements.
Except as required by law, the Company does not intend to
revise or update these forward-looking statements after the date
hereof or to revise them to reflect the occurrence of future
unanticipated events.
Contact:
Mike Withrow
1-778-896-6536
Abattis Bioceuticals (CE) (USOTC:ATTBF)
Historical Stock Chart
From Dec 2024 to Jan 2025
Abattis Bioceuticals (CE) (USOTC:ATTBF)
Historical Stock Chart
From Jan 2024 to Jan 2025
